The eukaryotic translation elongation factor 1 delta (EEF1D) antibody is a research tool targeting the EEF1D protein, a subunit of the eEF1B complex involved in protein synthesis. EEF1D functions as a guanine nucleotide exchange factor (GEF) for eEF1A, facilitating GTP replenishment during the elongation phase of translation. Beyond its canonical role, EEF1D has been implicated in diverse cellular processes, including cytoskeletal organization, apoptosis regulation, and viral replication.
Studies highlight EEF1D's dysregulation in cancers (e.g., breast, liver, and colorectal), neurological disorders, and developmental defects, positioning it as a potential biomarker or therapeutic target. Antibodies against EEF1D are widely used in techniques like Western blotting, immunofluorescence, and co-immunoprecipitation to investigate its expression patterns, subcellular localization, and interaction partners.
Commercial EEF1D antibodies are typically raised in hosts like rabbits or mice, targeting specific epitopes (e.g., N-terminal or C-terminal regions). Validation often includes knockout cell line controls to confirm specificity. Researchers also utilize these antibodies to explore post-translational modifications (e.g., phosphorylation) that modulate EEF1D's activity in stress responses or disease pathways. Its dual role in translation fidelity and non-ribosomal functions continues to drive interest in mechanistic studies across molecular biology and biomedicine.